Enzymatica publ AB (ENZY) - Total Liabilities
Based on the latest financial reports, Enzymatica publ AB (ENZY) has total liabilities worth Skr13.56 Million SEK (≈ $1.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ENZY cash flow metrics to assess how effectively this company generates cash.
Enzymatica publ AB - Total Liabilities Trend (2007–2024)
This chart illustrates how Enzymatica publ AB's total liabilities have evolved over time, based on quarterly financial data. Check Enzymatica publ AB liquidity resilience to evaluate the company's liquid asset resilience ratio.
Enzymatica publ AB Competitors by Total Liabilities
The table below lists competitors of Enzymatica publ AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Teuton Resources Corp.
V:TUO
|
Canada | CA$61.65K |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
USA | $1.92 Billion |
|
TROPHY GAMES Development AS
CO:TGAMES
|
Denmark | Dkr11.62 Million |
|
Sunsuria Bhd
KLSE:3743
|
Malaysia | RM1.27 Billion |
|
International Development & Investment Corp
VN:IDI
|
Vietnam | ₫6.03 Trillion |
|
Formet Celik Kapi Sanayi ve Ticaret AS
IS:FORMT
|
Turkey | TL712.26 Million |
|
Pancontinental Energy NL
AU:PCL
|
Australia | AU$670.24K |
|
International Media Acquisition Corp
NASDAQ:IMAQ
|
USA | $15.25 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Enzymatica publ AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ENZY stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.47 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enzymatica publ AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enzymatica publ AB (2007–2024)
The table below shows the annual total liabilities of Enzymatica publ AB from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr18.86 Million ≈ $2.03 Million |
-61.76% |
| 2023-12-31 | Skr49.30 Million ≈ $5.31 Million |
+2.46% |
| 2022-12-31 | Skr48.12 Million ≈ $5.18 Million |
+50.06% |
| 2021-12-31 | Skr32.07 Million ≈ $3.45 Million |
-42.09% |
| 2020-12-31 | Skr55.38 Million ≈ $5.96 Million |
+94.26% |
| 2019-12-31 | Skr28.51 Million ≈ $3.07 Million |
+11.74% |
| 2018-12-31 | Skr25.51 Million ≈ $2.75 Million |
+10.33% |
| 2017-12-31 | Skr23.12 Million ≈ $2.49 Million |
+12.26% |
| 2016-12-31 | Skr20.60 Million ≈ $2.22 Million |
-5.80% |
| 2015-12-31 | Skr21.87 Million ≈ $2.35 Million |
+124.44% |
| 2014-12-31 | Skr9.74 Million ≈ $1.05 Million |
-5.32% |
| 2013-12-31 | Skr10.29 Million ≈ $1.11 Million |
+424.20% |
| 2012-12-31 | Skr1.96 Million ≈ $211.25K |
+47.59% |
| 2011-12-31 | Skr1.33 Million ≈ $143.13K |
-55.47% |
| 2010-12-31 | Skr2.99 Million ≈ $321.45K |
+40.67% |
| 2009-12-31 | Skr2.12 Million ≈ $228.51K |
+21.62% |
| 2008-12-31 | Skr1.75 Million ≈ $187.90K |
+87.94% |
| 2007-12-31 | Skr929.00K ≈ $99.98K |
-- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.